Tofacitinib — Membership Pricing

Other medications in Rheumatology

• Upadacitinib
• Voclosporin
• Abatacept
• Anakinra
• Anifrolumab
• Baricitinib
• Belimumab
• Canakinumab

About Tofacitinib

Tofacitinib, often known by its brand name Xeljanz, is a targeted medication used to treat various autoimmune conditions. While highly effective, its cost can be a significant concern for many. TheDrugClub is dedicated to helping members access vital medications like tofacitinib more affordably, ensuring you can prioritize your health without undue financial stress.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Tofacitinib is approved for (FDA label)

Tofacitinib tablets are Janus kinase (JAK) inhibitors. Tofacitinib tablets are indicated for the treatment of adult patients with: Moderately to severely active rheumatoid arthritis (RA), who have had an inadequate response or intolerance to one or more TNF blockers. Active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to one or more TNF blockers. Active ankylosing spondylitis (AS), who have had an inadequate response or intolerance to one or more TNF blockers. Moderately to severely active ulcerative colitis (UC), who have had an inadequate response or intolerance to one or more TNF blockers.

Source: Read the full FDA label on DailyMed. Label effective date: September 1, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Tofacitinib (FDA label)

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS SERIOUS INFECTIONS Patients treated with tofacitinib tablets are at increased risk for developing serious bacterial, fungal, viral, and opportunistic infections, including tuberculosis (TB), that may lead to hospitalization or death [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Reported infections included: Active TB, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent TB before tofacitinib tablets use and during therapy. Treatment for latent infection should be initiated prior to tofacitinib tablets use. Invasive fungal infections, including cryptococcosis and pneumocystosis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease. Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens. The risks and benefits of tofacitinib tablets treatment should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after tofacitinib tablets treatment, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

Source: FDA prescribing information (DailyMed). Set ID: 253635c8-1ea7-41ba-b216-dea5e3305c47. SPL document ID: 25aada50-1f94-495f-9c11-8e2e9f282994. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Tofacitinib (FDA label)

Tofacitinib tablets: 5 mg tofacitinib: White to off white colored, round shaped, biconvex, film-coated tablets, debossed with “T1” on one side and “M” on other side. 10 mg tofacitinib: Blue colored, round shaped, biconvex, film-coated tablets, debossed with “T2” on one side and “M” on other side. Tofacitinib tablets: 5 mg, 10 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 253635c8-1ea7-41ba-b216-dea5e3305c47. SPL document ID: 25aada50-1f94-495f-9c11-8e2e9f282994. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Tofacitinib (FDA label)

The following clinically significant adverse reactions are described elsewhere in the labeling: Serious Infections [see Warnings and Precautions (5.1) ] Increased Risk of Mortality [see Warnings and Precautions (5.2) ] Malignancy and Lymphoproliferative Disorders [see Warnings and Precautions (5.3) ] Major Adverse Cardiovascular Events [see Warnings and Precautions (5.4) ] Thrombosis [see Warnings and Precautions (5.5) ] Gastrointestinal Perforations [see Warnings and Precautions (5.6) ] Hypersensitivity Reactions [see Warnings and Precautions (5.7) ] Hypoglycemia in Patients with Diabetes [ see Warnings and Precautions (5.8) ] Laboratory Abnormalities [ see Warnings and Precautions (5.9) ] Most common adverse reactions are: RA, PsA, and AS: Reported in ≥2% of adult patients treated with tofacitinib tabletsmonotherapy or in combination with DMARDs: upper respiratory tract infection (URI), nasopharyngitis, diarrhea, and headache. ( 6.1 ) PcJIA: Consistent with common adverse reactions reported in adult patients with RA. ( 6.1 ) UC: Reported in ≥5% of adult patients treated with tofacitinib tabletsand ≥1% greater than reported in patients treated with placebo: nasopharyngitis, elevated cholesterol levels, headache, URI, increased blood creatine phosphokinase, rash, diarrhea, and herpes zoster. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Novadoz Pharmaceuticals LLC at 1-855-668-2369 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not predict the rates observed in a broader patient population in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: 253635c8-1ea7-41ba-b216-dea5e3305c47. SPL document ID: 25aada50-1f94-495f-9c11-8e2e9f282994. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Tofacitinib (FDA label)

None. None. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 253635c8-1ea7-41ba-b216-dea5e3305c47. SPL document ID: 25aada50-1f94-495f-9c11-8e2e9f282994. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Tofacitinib (FDA label)

Serious Infections: Avoid use of tofacitinib tablets during an active serious infection, including localized infections. ( 5.1 ) Gastrointestinal Perforations: Promptly evaluate patients at increased risk for gastrointestinal perforation who present with new onset abdominal symptoms. ( 5.6 ) Hypoglycemia in Patients with Diabetes: Consider increased monitoring of blood glucose; advise patients with diabetes to notify their healthcare provider if they develop signs or symptoms of hypoglycemia. ( 5.8 ) Laboratory Monitoring: Recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids. ( 5.9 ) Vaccinations: Avoid use of live vaccines concurrently with tofacitinib. ( 5.10 ) 5.1 Serious Infections Serious and sometimes fatal infections may occur with tofacitinib tablets. Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving tofacitinib tablets.

Source: FDA prescribing information (DailyMed). Set ID: 253635c8-1ea7-41ba-b216-dea5e3305c47. SPL document ID: 25aada50-1f94-495f-9c11-8e2e9f282994. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Tofacitinib (FDA label)

Table 7 includes drugs with clinically significant drug interactions when concomitantly used with tofacitinib tablets and instructions for preventing or managing them.

Source: FDA prescribing information (DailyMed). Set ID: 253635c8-1ea7-41ba-b216-dea5e3305c47. SPL document ID: 25aada50-1f94-495f-9c11-8e2e9f282994. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.